Nimenrix vaccine

Indications

• Carnitine deficiency
• Hyperlipoproteinemias
• Treatment of metabolic disorders involving fatty acid oxidation
• Supportive therapy in conditions associated with increased metabolic demands

Dosage

Children: Refer to the BNF for Children for appropriate paediatric dosing

Adults: Refer to the BNF for specific dosing guidelines as they may vary by condition and formulation.

Mechanism of action

Levocarnitine functions as a carrier molecule that transports long-chain fatty acids across the inner mitochondrial membrane. It also exports acyl groups from subcellular organelles and cells to urine, mitigating the risk of toxic accumulation. The L isomer specifically influences lipid metabolism and is involved in various pathways including carnitine transporters and translocases. Additionally, it acts as a peripheral antagonist of thyroid hormone action in certain tissues, inhibiting thyroid hormone entry into cell nuclei.

Pharmacodynamics

Levocarnitine is essential for lipid metabolism and helps prevent the toxic effects associated with carnitine deficiency, which can lead to complications in liver, heart, and muscle function. A deficiency is characterized by low plasma concentrations of free carnitine and may be associated with elevated acylcarnitine levels. Therapeutically, levocarnitine can stimulate gastric and pancreatic secretions and is used in treating hyperlipoproteinemias.

Pharmacokinetics

Levocarnitine is absorbed in the gastrointestinal tract, with bioavailability affected by dietary intake and individual metabolism. It is distributed throughout the body, particularly in muscle tissues, where it is utilized for fatty acid oxidation. The compound is metabolized in the liver and excreted primarily through urine. The half-life and elimination can vary based on the individual's health status and renal function.

Adverse effects

• Nausea
• Vomiting
• Diarrhea
• Abdominal cramps
• Fishy body odor
• Increased appetite

Interactions

• Anticoagulants
• Thyroid hormones

Precautions

• Use with caution in patients with renal impairment
• Monitor for signs of gastrointestinal distress
• Assess for underlying carnitine deficiency before use

Pregnancy

Levocarnitine should be used during pregnancy only if clearly needed, as safety in pregnancy has not been fully established.

Breast-feeding

Levocarnitine is excreted in breast milk; caution should be exercised when administered to nursing mothers.

Storage

Store at room temperature, away from moisture and heat. Keep in a tightly closed container.

Formulations

• Oral solution
• Tablet
• Injection

Dosage

Children: Refer to specific drug monographs for detailed paediatric dosage information, as this will also vary widely among drugs within any given group.

Adults: Refer to specific drug monographs for detailed dosage information, as this will vary widely among drugs within any given group.

Mechanism of action

The mechanism of action for drugs within a group can vary. For example, antihypertensive drugs may work by relaxing blood vessels, reducing heart rate, or decreasing blood volume. Analgesics can work by inhibiting pain pathways in the central nervous system or blocking the production of pain-inducing chemicals. Each individual drug within a group will have its specific pathway and target molecules, such as receptors or enzymes, which are involved in its therapeutic effects.

Pharmacodynamics

Pharmacodynamics describes how a drug affects the body. Within any given drug group, the pharmacodynamics can include the drug's affinity for its target receptors, the efficacy in producing a biological response, and the onset and duration of action. For instance, some analgesics may produce rapid relief of pain, while others may have delayed effects. The dose-response relationship, which indicates how the effects of a drug change with varying doses, is also a crucial aspect of pharmacodynamics.

Pharmacokinetics

Pharmacokinetics encompasses the absorption, distribution, metabolism, and excretion (ADME) of a drug. For drugs within a group, pharmacokinetic parameters can differ significantly. Factors such as bioavailability, half-life, volume of distribution, and clearance rates are important for determining dosing regimens and understanding how long a drug will exert its effects in the body. For example, some antibiotics may be rapidly absorbed and cleared, necessitating more frequent dosing, while others may have extended half-lives allowing for less frequent administration.

Pregnancy

The safety of this drug during pregnancy has not been fully established. It should only be used if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known whether this drug is excreted in human milk. Caution should be exercised when administering to nursing mothers.

Storage

Store in a cool, dry place, away from direct sunlight. Keep out of reach of children.

Indications

• Bacterial meningitis
• Viral meningitis
• Preventive vaccination against meningococcal disease
• Post-exposure prophylaxis in cases of meningococcal infection

Dosage

Children: Refer to the BNF for Children for dosing recommendations, which will vary based on the specific antibiotic used and the age and weight of the child.

Adults: Refer to local guidelines and the BNF for specific antibiotic dosing regimens according to the pathogen identified and clinical presentation.

Mechanism of action

In cases of bacterial meningitis, antibiotics such as penicillins or cephalosporins work by inhibiting cell wall synthesis, leading to bacterial cell lysis and death. In the context of meningococcal meningitis caused by Neisseria meningitidis, meningococcal vaccines stimulate the immune response against the bacteria, allowing the body to mount an effective defense against future infections.

Pharmacodynamics

The pharmacodynamics of antibiotics used in the treatment of meningitis involve their ability to penetrate the blood-brain barrier, which is crucial for effective treatment of central nervous system infections. The efficacy of these agents is often determined by their ability to achieve adequate concentrations in the cerebrospinal fluid (CSF). Vaccines elicit the production of specific antibodies, providing immunity against the pathogens causing meningitis.

Pharmacokinetics

Pharmacokinetics of antibiotics vary depending on their class. For example, penicillins have good distribution in the CSF, especially when inflammation of the meninges is present. The half-life, metabolism, and excretion routes also vary. Vaccines generally stimulate a long-lasting immune response but do not have a conventional pharmacokinetic profile as they do not act like drugs in the traditional sense.

Pregnancy

Meningococcal vaccines are generally considered safe during pregnancy. However, consult healthcare providers for specific cases.

Breast-feeding

The meningococcal vaccine is safe during breastfeeding. Consult healthcare providers for individual assessment.

Storage

Store at 2 to 8 degrees Celsius. Do not freeze. Protect from light.

Indications

• Meningococcal disease (caused by Neisseria meningitidis)
• Gonorrhea (caused by Neisseria gonorrhoeae)
• Pelvic inflammatory disease
• Septic arthritis

Dosage

Children: Refer to appropriate clinical guidelines for specific dosing of antibiotics used to treat

Adults: Refer to appropriate clinical guidelines for specific dosing of antibiotics used to treat Neisseria infections.

Mechanism of action

Neisseria species adhere to and invade epithelial cells through the action of pili and outer membrane proteins. They evade the immune response by varying their surface antigens and producing factors such as endotoxin and proteases. Neisseria meningitidis can enter the bloodstream and cross the blood-brain barrier, leading to inflammation and potentially severe outcomes such as meningitis or septicemia. Neisseria gonorrhoeae primarily infects the urogenital tract and can cause local inflammation and complications if untreated.

Pharmacodynamics

The pathogenesis of Neisseria involves complex interactions with the host's immune system, including the ability to resist phagocytosis. The bacteria can produce a polysaccharide capsule, particularly in Neisseria meningitidis, which enhances virulence by inhibiting opsonization and phagocytosis. The inflammatory response to these infections can lead to symptoms such as fever, headache, and, in the case of meningitis, neck stiffness.

Pharmacokinetics

Neisseria species do not have a defined pharmacokinetic profile as they are pathogens rather than drugs. However, the pharmacokinetics of antibiotics used to treat infections caused by Neisseria, such as penicillin or ceftriaxone, would be relevant. These antibiotics are typically well-absorbed, distributed throughout the body, and excreted by the kidneys, with adjustments needed for renal impairment.

Pregnancy

There is limited data on the use of Neisseria species during pregnancy. Caution is advised, and benefits should be weighed against potential risks.

Breast-feeding

Caution is advised when administering medications targeting Neisseria species during breastfeeding due to limited data on excretion in human milk.

Storage

Store in a cool, dry place, away from direct sunlight. Specific storage requirements may vary based on the formulation and manufacturer's guidelines.

Indications

• Nutritional supplementation
• Muscle repair and growth
• Immune support
• Enzyme replacement therapy
• Hormonal regulation

Dosage

Children: Refer to specific product guidelines for dosing information, as protein requirements in children vary based on age, growth stage, and health status.

Adults: Refer to specific product guidelines for dosing information, as protein requirements can vary widely based on individual needs, activity levels, and clinical conditions.

Mechanism of action

Proteins exert their effects primarily through their structure and interactions with other molecules. They can function as enzymes, hormones, and antibodies, and their action is often mediated by binding to specific receptors or substrates, leading to a change in cellular activity or function. For example, enzymes catalyze biochemical reactions, while antibodies bind to antigens to facilitate immune responses.

Pharmacodynamics

The pharmacodynamics of proteins can vary significantly depending on the specific protein being considered. Generally, the effects of proteins are dose-dependent and influenced by their concentration, affinity for targets, and duration of action. Proteins can have a wide range of biological activities, including promoting cellular repair, regulating metabolism, and modulating immune responses.

Pharmacokinetics

The pharmacokinetics of proteins includes their absorption, distribution, metabolism, and excretion (ADME). Proteins are typically digested in the gastrointestinal tract into amino acids before being absorbed into the bloodstream. Once in circulation, proteins can be distributed throughout various tissues. They may have a variable half-life based on their structure and function, and they are primarily metabolized by the liver and excreted via the kidneys. The pharmacokinetic profile can be influenced by factors such as the route of administration and the presence of other substances.

Pregnancy

Generally considered safe, but high protein intake should be monitored to avoid potential risks.

Breast-feeding

Adequate protein intake is critical for lactating women to support milk production and quality.

Storage

Store in a cool, dry place, away from direct sunlight.

Indications

• Tetanus prophylaxis
• Treatment of tetanus infection
• Management of tetanus symptoms

Dosage

Children: Refer to the specific guidelines for tetanus immunoglobulin and other supportive treatments as per clinical protocols.

Adults: Refer to the specific guidelines for tetanus immunoglobulin and other supportive treatments as per clinical protocols.

Mechanism of action

The tetanus toxin binds to the presynaptic membrane of motor neurons and is transported retrogradely to the spinal cord, where it interferes with neurotransmitter release, particularly inhibiting the release of glycine and gamma-aminobutyric acid (GABA), leading to unopposed motor neuron activity and resultant muscle rigidity and spasms.

Pharmacodynamics

Tetanus toxin is one of the most potent toxins known, with effects that can manifest within hours of exposure. The toxin's ability to block inhibitory neurotransmitter release results in a state of continuous muscle contraction, known as tetany. The clinical presentation of tetanus includes trismus (lockjaw), muscle rigidity, and autonomic instability, among others.

Pharmacokinetics

The pharmacokinetics of tetanus toxin are complex due to its high potency and the nature of its action. Following entry into the body, the toxin binds to nerve endings and is internalized, leading to its effects on neurotransmitter release. The half-life of the toxin is not well defined as it does not circulate freely in the bloodstream but acts locally at the neuromuscular junction. Recovery from the effects of the toxin may take weeks to months, depending on the severity of the infection and the treatment provided.

Adverse effects

• Pain at the injection site
• Fever
• Fatigue
• Headache
• Nausea

Precautions

• Ensure patient is up to date with vaccinations
• Monitor for allergic reactions post-vaccination
• Consider history of neurological disorders

Pregnancy

Tetanus vaccination is considered safe during pregnancy and is recommended to protect both the mother and the newborn.

Breast-feeding

Tetanus vaccination is safe during breastfeeding and does not affect the nursing infant.

Storage

Store in a refrigerator at 2–8 degrees Celsius. Do not freeze.

Formulations

• Tetanus toxoid vaccine

Indications

• Diphtheria prophylaxis
• Tetanus prophylaxis
• Pertussis prophylaxis (when combined with other vaccines)

Dosage

Children: Refer to the BNF for Children for specific dosing recommendations for pediatric immunization with toxoids.

Adults: Refer to specific guidelines for each toxoid vaccine, as dosing may vary based on the type of vaccine and individual patient factors.

Mechanism of action

Toxoids work by stimulating the immune system to produce antibodies against the toxin without causing disease. When administered, the immune system recognizes the toxoid as a foreign substance and generates a specific immune response. This includes the production of immunoglobulin G (IgG) antibodies that can neutralize the active toxin if the individual is exposed to the bacteria in the future.

Pharmacodynamics

The pharmacodynamics of toxoids involve the activation of the adaptive immune response. After vaccination, dendritic cells present the antigen to T cells, which then help B cells differentiate into plasma cells that produce specific antibodies. The presence of these antibodies provides immunity against the toxin by neutralizing its effects, thereby preventing the disease associated with the original bacterial toxin.

Pharmacokinetics

Toxoids are typically administered via intramuscular or subcutaneous injection. Following administration, they are gradually taken up by antigen-presenting cells, which then process and present the toxoid to T cells. The immunogenic response can develop over several weeks. The duration of immunity can vary, necessitating booster doses to maintain adequate antibody levels over time.

Adverse effects

• Local reactions at the injection site, such as pain, swelling, or redness.
• Fever.
• Fatigue.
• Headache.
• Allergic reactions in rare cases.

Precautions

• Use with caution in individuals with a history of severe allergic reactions to a vaccine component.
• Monitor patients for allergic reactions post-vaccination.

Pregnancy

Toxoids are generally considered safe during pregnancy; however, consultation with a healthcare provider is recommended.

Breast-feeding

Toxoids are considered safe for use during breastfeeding.

Storage

Store in a refrigerator at 2-8°C. Do not freeze. Protect from light.

Formulations

• Diphtheria toxoid
• Tetanus toxoid
• Pertussis toxoid

Mechanism of action

Levocarnitine can be synthesised within the body from the amino acids lysine or methionine. Vitamin C (ascorbic acid) is essential to the synthesis of carnitine. Levocarnitine is a carrier molecule in the transport of long chain fatty acids across the inner mitochondrial membrane. It also exports acyl groups from subcellular organelles and from cells to urine before they accumulate to toxic concentrations. Only the L isomer of carnitine (sometimes called vitamin BT) affects lipid metabolism. Levocarnitine is handled by several proteins in different pathways including carnitine transporters, carnitine translocases, carnitine acetyltransferases and carnitine palmitoyltransferases. L-Carnitine is a peripheral antagonist of thyroid hormone action in some tissues. It inhibits thyroid hormone entry into cell nuclei. In a controlled clinical trial, L-carnitine was shown to reverse or prevent some symptoms of hyperthyroidism. ... Mortality and metabolic consequences of acute ammonium intoxication in mice are reduced by pharmacologic admin of L-carnitine. The mechanism for this effect may have 2 components. L-Carnitine admin normalizes the redox state of the brain (perhaps by incr the avail of beta-hydroxybutyrate and/or acetyl-L-carnitine to the brain), and it incr the rate of urea synth in the liver, perhaps in part by activation of the glucocorticoid receptor. At least part of the protective effect is associated with flux through the carnitine acyltransferases, as analogs of L-carnitine that are competitive inhibitors of carnitine acyltransferases enhance the toxicity of acute ammonium admin. Thus, it has been proposed that L-carnitine incr urea synth in the liver by facilitating fatty acid entry into mitochondria, leading to incr flux through the beta-oxidation pathway, an incr of intramitochondrial reducing equivalents, and enhancement of ATP production. ... Levocarnitine is necessary for normal mammalian fat utilization and energy metabolism. It facilitates entry of long-chain fatty acids into cellular mitochondria, where they are used during oxidation and energy production. It also exports acyl groups from subcellular organelles and from cells to urine before they accumulate to toxic concentrations. Carnitine's primary mechanism of action is apparently attributable to its role as a cofactor in the transformation of free long-chain fatty acids into acylcarnitines for subsequent transport into the mitochondrial matrix. Carnitine is involved in the metabolism of ketones for energy and the conversion of branched-chain amino acids - valine, leucine, and isoleucine - into energy. /Carnitine/ L-Carnitine participates in a reversible transesterification reaction, in which an acyl group is transferred from coenzyme A to the hydroxyl group of L-carnitine ... /This reaction facilitates the/ transfer of long-chain fatty acids from cytoplasm ... /and/ chain-shortened /very-long-chain/ fatty acids from peroxisomes to mitochondria /and the/ modulation of the acyl-CoA/CoA ratio in cellular compartments.

Pharmacodynamics

Levocarnitine is a carrier molecule in the transport of long chain fatty acids across the inner mitochondrial membrane. It also exports acyl groups from subcellular organelles and from cells to urine before they accumulate to toxic concentrations. Lack of carnitine can lead to liver, heart, and muscle problems. Carnitine deficiency is defined biochemically as abnormally low plasma concentrations of free carnitine, less than 20 µmol/L at one week post term and may be associated with low tissue and/or urine concentrations. Further, this condition may be associated with a plasma concentration ratio of acylcarnitine/levocarnitine greater than 0.4 or abnormally elevated concentrations of acylcarnitine in the urine. Only the L isomer of carnitine (sometimes called vitamin BT) affects lipid metabolism. The "vitamin BT" form actually contains D,L-carnitine, which competitively inhibits levocarnitine and can cause deficiency. Levocarnitine can be used therapeutically to stimulate gastric and pancreatic secretions and in the treatment of hyperlipoproteinemias.